603566.SH
Pulike Biological Engineering, Inc.
SSE · Healthcare · Biotechnology · CN
CNY 9.19
−1.92%Oct 26, 2026, 09:14 UTC
Pulike reported first-nine-month 2026 revenue of 738 million yuan, down 10.32% year over year, and net profit of 79.545 million yuan, down 49.38%.
Source:Oct 26, 2026, 09:14 UTC
Pulike reported third-quarter 2026 revenue of 247 million yuan, down 6.38% year over year, and net profit of 2.2207 million yuan, down 94.58%.
Source:Oct 12, 2026, 09:56 UTC
China’s Ministry of Agriculture and Rural Affairs approved Pulike’s African swine fever subunit vaccine for clinical trials at approved trial sites.
Source:Sep 14, 2026, 08:11 UTC
Pulike's wholly owned subsidiary Luoyang Huizhong Veterinary Medicine received a Class II new veterinary drug registration certificate from China's Ministry of Agriculture and Rural Affairs for Denaverine Hydrochloride Injection on September 14, 2026.
Source:Aug 24, 2026, 09:01 UTC
Pulike Biological Engineering announced its H1 2026 results with revenue of 491 million yuan, down 12.18% year-on-year, and net profit attributable to shareholders of 77.32 million yuan, down 33.45% year-on-year.
Source:Jul 21, 2026, 09:03 UTC
Pulike's controlled subsidiary Zhongpu Biological Pharmaceutical Co., Ltd. received veterinary drug product approval numbers from the Ministry of Agriculture and Rural Affairs for two foot-and-mouth disease vaccines, enabling production.